Tuberculosis and Respiratory Diseases

  • 제70권1호
  • /
  • Pages.69-73
  • /
  • 2011
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

페그-인터페론과 리바비린 병합치료 중 발생한 간질성 폐렴 및 범혈구 감소증 1예

A Case of Interstitial Pneumonitis and Pancytopenia Following the Combination Therapy of Pegylated Interferon and Ribavirin

  • 서지현 (단국대학교 의과대학 내과학교실) ;
  • 한성환 (단국대학교 의과대학 내과학교실) ;
  • 이지은 (단국대학교 의과대학 내과학교실) ;
  • 한진형 (단국대학교 의과대학 내과학교실) ;
  • 김경묵 (단국대학교 의과대학 내과학교실) ;
  • 김도형 (단국대학교 의과대학 내과학교실) ;
  • 김윤섭 (단국대학교 의과대학 내과학교실) ;
  • 박재석 (단국대학교 의과대학 내과학교실) ;
  • 지영구 (단국대학교 의과대학 내과학교실)
  • Suh, Ji-Hyun (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Hahn, Sung-Hwahn (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Lee, Ji-Eun (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Han, Jin-Hyung (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Kim, Kyung-Mook (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Kim, Doh-Hyung (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Kim, Yon-Seop (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Park, Jae-Suk (Department of Internal Medicine, Dankook University College of Medicine) ;
  • Jee, Young-Koo (Department of Internal Medicine, Dankook University College of Medicine)
  • 투고 : 2010.08.05
  • 심사 : 2010.10.06
  • 발행 : 2011.01.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The combination therapy of pegylated interferon and ribavirin is the mainstay of treatment for chronic hepatitis C patients. Anti-viral therapy is commonly associated with side effects such as headache, fever, myalgia, and arthralgia. However, anti-viral therapy can continue because these side effects are mostly mild and can be improved with supportive management. Anti-viral therapy should be stopped promptly if serious side effects, such as interstitial pneumonitis or hemolytic anemia occur, although those serious side effects are rare. There were a few case reports of interferon-related interstitial pneumonitis worldwide. In Korea, one atypical case report of interstitial pneumonitis has been reported, which followed the combination therapy of interferon-alpha and ribavirin in a patient with chronic hepatitis C. We present a case of interstitial pneumonitis and pancytopenia following the combination therapy of pegylated interferon and ribavirin in a patient with chronic hepatitis C.

키워드

참고문헌

  1. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19: 1-46.
  2. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71. https://doi.org/10.1002/hep.20119
  3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65. https://doi.org/10.1016/S0140-6736(01)06102-5
  4. Hwang SY, Lee HJ, Park KT, Kim KY, Lee SM, Park CW, et al. Effectiveness and complications of combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C. Korean J Gastroenterol 2007;49:166-72.
  5. Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994;105:939-41. https://doi.org/10.1378/chest.105.3.939
  6. Abi-Nassif S, Mark EJ, Fogel RB, Hallisey RK Jr. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. Chest 2003;124:406-10. https://doi.org/10.1378/chest.124.1.406
  7. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91. https://doi.org/10.1016/S0168-8278(96)80113-9
  8. Jeong HS, Oh JY, Jeon J, Seo MJ, Moon SH, Kim HS, et al. A case of interstitial pneumonitis after interferon therapy for chronic hepatitis C. Korean J Gastroenterol 1999;34:698-703.
  9. Sohn BK, Sohn JH, Kim TY, Park YK, Jeon YC, Han DS. Pulmonary Toxicity by Pegylated Interferon $\alpha$-2a in a Patient with Chronic Hepatitis C. Korean J Hepatol 2007;13:103-7.
  10. Kang MJ, Jung EU, Park SW, Choi P, Kim JH, Park SJ, et al. Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection. Korean J Hepatol 2008;14:318-30. https://doi.org/10.3350/kjhep.2008.14.3.318
  11. Cheong HR, Woo HY, Heo J, Yoon KT, Kim DU, Kim GH, et al. Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection. Korean J Hepatol 2010;16:38-48. https://doi.org/10.3350/kjhep.2010.16.1.38
  12. Hoffmann RM, Jung MC, Motz R, Gossl C, Emslander HP, Zachoval R, et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998;28:1058-63.
  13. Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 1994; 106:612-3. https://doi.org/10.1378/chest.106.2.612
  14. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration 2004;71:301-26. https://doi.org/10.1159/000079633